阿拉丁小分子抑制剂、激动剂、拮抗剂--G蛋白偶联受体信号通路（上）
G蛋白偶联受体
G蛋白偶联受体（GPCRs）是一类与G蛋白偶联的细胞表面受体，具有7个跨膜α螺旋结构。G蛋白偶联受体(GPCRs)能接受许多细胞外信号并传递给G蛋白，进而启动细胞内不同的信号转导通路。GPCRs介导对环境刺激物、神经递质、激素、细胞因子和脂质信号分子的多种生理反应，从而在视觉、嗅觉、自主神经系统和行为等生物过程中发挥着重要作用。GPCRs还与众多疾病相关，是治疗许多疾病的重要靶点之一。异常的GPCR功能与病理状态有关，如神经、免疫和激素紊乱等。
G蛋白偶联受体信号通路转导过程
G 蛋白偶联受体可被多种不同的外界刺激激活。当配体与GPCRs结合时，激活附着在细胞内侧端的G蛋白（由α、β、γ三个亚基组成的异源三聚体）。G蛋白上原本结合的GDP被GTP取代，导致α亚基与β-γ亚基复合物解离，并触发各种不同的信号级联放大，激活下游信号通路。这些细胞内信号通路包括cAMP/PKA、钙/NFAT、磷脂酶C（PLC)、蛋白酪氨酸激酶、MAP激酶、PI3K、NO/cGMP、Rho和JAK/STAT等，从而作用于相应的靶分子，进而调控代谢过程及基因表达功能。
G蛋白偶联受体信号通路图
产品列表
按靶点分类：
*5-HT受体
| 项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 | Ki | pKi |
|---|---|---|---|---|---|---|---|---|---|
| F131623 | Fluoxetine HCl | ≥98%(HPLC) | 56296-78-7 | 1g,5g,25g | 5-HT | 0.1 pM | |||
| V129637 | Venlafaxine hydrochloride | ≥98%(HPLC) | 99300-78-4 | 1g,5g,25g,100g | 5-HT | ||||
| D129639 | Dapoxetine hydrochloride | ≥98%(HPLC) | 129938-20-1 | 250mg,1g,5g | 5-HT | ||||
| I125279 | Iloperidone | ≥98% | 133454-47-4 | 50mg,250mg,1g,5g | 5-HT | ||||
| V129787 | Vortioxetine (Lu AA21004) HBr | ≥98% | 960203-27-4 | 5mg,25mg,100mg | 5-HT1A | 15 nM | |||
| 5-HT1B | 33 nM | ||||||||
| 5-HT3A | 3.7 nM | ||||||||
| 5-HT7受体 | 19 nM | ||||||||
| SERT | 1.6 nM | ||||||||
| F129671 | Fluvoxamine maleate | ≥98% | 61718-82-9 | 250mg,1g,5g,25g,100g | 5-HT | ||||
| S129789 | Sertraline HCl | ≥98% (HPLC) | 79559-97-0 | 1g,5g | 5-HT | ||||
| L129555 | Lamotrigine | ≥98% | 84057-84-1 | 1g,5g | 人类血小板 | 5-HT | 240 μM | ||
| 大鼠脑突触体 | 5-HT | 474 μM | |||||||
| C129687 | Clomipramine HCl | ≥99% | 17321-77-6 | 1g,5g,25g | 5-HT | ||||
| E122736 | 草酸右旋西酞普兰 | 98% | 219861-08-2 | 50mg,250mg,1g,5g | 5-HT | 0.89 nM | |||
| D123291 | 盐酸度洛西汀 | ≥98.0%(HPLC) | 136434-34-9 | 1g,5g,25g | 5-HT | ||||
| M129386 | Milnacipran hydrochloride | ≥99% | 101152-94-7 | 10mg,50mg,250mg,500mg,1g,5g,25g | NET | 77 nM | |||
| SERT | 420 nM | ||||||||
| A129730 | 盐酸阿米替林 | ≥98% | 549-18-8 | 1g,5g,25g,100g | 5-羟色胺受体 | 3.45 nM | |||
| 去甲肾上腺素受体 | 13.3 nM | ||||||||
| 5-HT4 | 7.31 nM | ||||||||
| 5-HT2 | 235 nM | ||||||||
| sigma 1受体 | 287 nM | ||||||||
| L174987 | Levomilnacipran hydrochloride | 97% | 175131-60-9 | 100mg,250mg,1g | |||||
| C122737 | 氢溴酸西酞 | 98% | 59729-32-7 | 1g,5g | serotonin reuptake | 1.8 nM | |||
| V129637 | Venlafaxine hydrochloride | ≥98% (HPLC) | 93413-69-5 | 1g,5g,25g,100g | SNRI | ||||
| D136408 | 盐酸去甲咪嗪 | ≥98% | 58-28-6 | 1g,5g,25g | |||||
| T129695 | 曲唑酮 盐酸盐 | 98% | 25332-39-2 | 1g | 5-HT | ||||
| P137447 | Protriptyline Hydrochloride | ≥98% | 1225-55-4 | 25mg,100mg | |||||
| A129721 | Atomoxetine HCl | ≥98% | 82248-59-7 | 50mg,250mg,1g | Norepinephrine (NE) transporter | 5 nM | |||
| 5-HT | 77 nM | ||||||||
| DA transporter | 1451 nM | ||||||||
| C126883 | 氯氮平 | ≥98%(GC) | 5786-21-0 | 100mg,1g,5g,25g,100g | 5-HT | 110 nM | |||
| O126519 | Olanzapine | ≥99% | 132539-06-1 | 1g,5g | 5-HT2 | ||||
| D2 receptor | |||||||||
| K129651 | Ketanserin | ≥97% | 74050-98-9 | 50mg,250mg,1g | 5-HT2A | 2.5 nM | |||
| 大鼠 | 5-HT2C | 50 nM | |||||||
| 人 | 5-HT2C | 100 nM | |||||||
| L129669 | Latrepirdine | ≥96% | 97657-92-6 | 5mg,10mg,50mg | |||||
| A129730 | 盐酸阿米替林 | ≥98% | 50-48-6 | 1g,5g,25g,100g | |||||
| A124691 | 阿戈美拉汀 | ≥98%(HPLC) | 138112-76-2 | 5mg,25mg,50mg,250mg,1g,5g,25g | 5-HT2C | ||||
| A124739 | Asenapine maleate | ≥98% (HPLC) | 85650-56-2 | 10mg,50mg,250mg,1g | |||||
| R127644 | Risperidone | ≥98% | 106266-06-2 | 500mg,5g,25g,100g | 5-HT2A | 0.17 nM | |||
| α2c-adrenergic receptor | 1.3 nM | ||||||||
| D2 receptor | 3.57 nM | ||||||||
| D3 receptor | 3.6 nM | ||||||||
| D2L Receptor | 4.16 nM | ||||||||
| E129717 | Ziprasidone HCl | ≥98% | 122883-93-6 | 250mg,1g | 5-HT receptor | ||||
| Dopamine receptor | |||||||||
| W129689 | WAY-100635 Maleate | ≥99% | 1092679-51-0 | 5mg,25mg,100mg | 5-HT | 0.95 nM | |||
| B129706 | Blonanserin | ≥98% (HPLC) | 132810-10-7 | 25mg,100mg | dopamine D2 receptor | 14.8 nM | |||
| 5-HT2 | 3.98 nM | ||||||||
| S129658 | SB269970 HCl | ≥99% | 261901-57-9 | 10mg,50mg | 5-HT7 | 8.3 | |||
| S125056 | SB269970 HCl | - | 261901-57-9 | 10mg | 5-HT7 | 8.3 | |||
| G120176 | 盐酸格拉司琼 | 98% | 107007-99-8 | 10mg,50mg,1g,5g | 5-HT3 | ||||
| M129297 | Mirtazapine | ≥98% | 85650-52-8 | 100mg,1g | 5-HT | ||||
| SB742457 | SB742457 | ≥97% | 607742-69-8 | 5mg,25mg | 5-HT6 | 9.63 | |||
| B129690 | BRL-15572 | ≥99% | 193611-72-2 | 5mg,10mg,50mg | 5-HT1D | 7.9 | |||
| P129785 | PRX-08066 Maleic acid | ≥99% | 866206-55-5 | 5mg,10mg,50mg | 5-HT2B | 3.4 nM | |||
| T124762 | 盐酸托烷司琼 | ≥98.0% | 105826-92-4 | 250mg,1g,5g | 5-HT3 | 70.1±0.9 nM | |||
| P129438 | Pizotifen Malate | ≥99% | 5189-11-7 | 100mg,500mg | |||||
| A129701 | Azasetron HCl | ≥99% | 123040-16-4 | 25mg,100mg | 5-HT3 | 0.33 nM | |||
| F129636 | 夫洛丙酮 | ≥99% | 2295-58-1 | 50mg | 5-HT1A | ||||
| O129694 | Ondansetron | ≥99% | 99614-02-5 | 10mg,50mg,250mg | 5-HT3 | ||||
| P129744 | Palonosetron HCl | ≥99% | 135729-62-3 | 100mg,500mg | 5-HT3 | ||||
| V129763 | VUF 10166 | ≥99% | 155584-74-0 | 10mg,50mg,250mg | 5-HT3A | 0.04 nM | |||
| 5-HT3AB | 22 nM | ||||||||
| N159830 | 奈法唑酮盐酸盐 | 98.00% | 82752-99-6 | 200mg,1g | |||||
| C101491 | 盐酸赛庚啶 | 98% | 41354-29-4 | 1g,5g,25g | 5-HT2 | 0.6 nM | |||
| O129679 | Ondansetron Hydrochloride Dihydrate | ≥98% (HPLC) | 103639-04-9 | 1g,5g | 5-HT3 receptor | 6.16 nM | |||
| A135530 | Alosetron Hydrochloride | ≥98% (HPLC) | 122852-69-1 | 1g,5g | 5-HT3 receptor | ||||
| S132232 | Sarpogrelate Hydrochloride | ≥98% | 135159-51-2 | 5mg,25mg,100mg | 5-HT2A | 8.52 | |||
| 5-HT2C | 7.43 | ||||||||
| 5-HT2B | 6.57 | ||||||||
| R166990 | Ramosetron hydrochloride | 98% (HPLC) | 132907-72-3 | 10mg,50mg,100mg,250mg | 5-HT3 receptor | 0.091 nM | |||
| P111270 | 葛根素 | 98% | 3681-99-0 | 1g,5g,25g,100g | 5-HT2C | ||||
| P111269 | 葛根素 | 分析标准品,≥98% | 3681-99-0 | 20mg | 5-HT2C | ||||
| C134704 | Cyclobenzaprine hydrochloride | 98% | 6202-23-9 | 1g,5g,25g | 5-HT2 receptor | ||||
| G127257 | Granisetron | - | 109889-09-0 | 25mg,50mg,100mg,250mg | 5HT-3 | ||||
| L129692 | LY310762 | ≥95% | 192927-92-7 | 10mg,50mg | 5-HT1D | 249 nM | |||
| P125293 | Palonosetron | - | 135729-61-2 | 10mg,100mg | 5-HT3 receptor | 0.17 nM | |||
| M124574 | 5-甲氧基色胺 | 97% | 608-07-1 | 250mg,1g,5g,25g | 5-HT1 | ||||
| 5-HT2 | |||||||||
| 5-HT4 | |||||||||
| 5-HT6 | |||||||||
| S129681 | Sumatriptan Succinate | ≥98% (HPLC) | 103628-48-4 | 50mg,100mg,250mg,1g | |||||
| P129662 | Prucalopride | ≥99% | 179474-81-8 | 10mg,50mg | 5-HT4A | 2.5 nM | |||
| 5-HT4B | 8 nM | ||||||||
| A124880 | Aripiprazole | ≥99% | 129722-12-9 | 1g,5g | 5-HT1A | 4.2 nM | |||
| N129630 | Naratriptan hydrochloride | ≥98% | 143388-64-1 | 10mg,25mg,50mg,100mg | 5-HT | ||||
| R129638 | Rizatriptan Benzoate | ≥98%(HPLC) | 145202-66-0 | 10mg,50mg,250mg,1g,5g | 5-HT1 | ||||
| Z129649 | Zolmitriptan | ≥98%(HPLC) | 139264-17-8 | 200mg,250mg,1g,5g,25g | 5-HT | ||||
| M129673 | Mosapride Citrate | ≥98% | 112885-42-4 | 10mg,50mg,250mg,1g,5g,25g | 5-HT4 | ||||
| E129729 | Eletriptan HBr | ≥98% | 177834-92-3 | 10mg,50mg,250mg,1g,5g | 5-HT1B | 0.92 nM | |||
| 5-HT1D | 3.14 nM | ||||||||
| A129703 | Almotriptan Malate | ≥99% | 181183-52-8 | 1g | 5-HT1B | ||||
| 5-HT1D | |||||||||
| T168187 | Tegaserod maleate | 98% (HPLC) | 189188-57-6 | 10mg,50mg | 5-HT4 receptor | ||||
| B129734 | BRL-54443 | ≥98% | 57477-39-1 | 10mg,50mg,100mg | 5-HT1E | 8.7 | |||
| 5-HT1F | 9.25 | ||||||||
| B178171 | brexpiprazole | 97% | 913611-97-9 | 1g | D2L | 0.3 nM | |||
| 5-HT1A | 0.12 nM | ||||||||
| 5-HT2A | 0.47 nM | ||||||||
| α1B受体 | 0.17 nM | ||||||||
| α2C受体 | 0.59 nM | ||||||||
| M179481 | Mosapride | 95% | 112885-41-3 | 1g,5g | 5HT4 | ||||
| S111161 | 血清胺盐酸盐 | AR | 153-98-0 | 1g,5g,25g | 5-HT | ||||
| V124992 | Vilazodone | ≥98% | 163521-12-8 | 10mg,50mg | |||||
| F167802 | Flibanserin | 98% (HPLC) | 167933-07-5 | 5mg,25mg | 5-HT1A | 1 nM | |||
| 5-HT2A | 49 nM | ||||||||
| F167802 | Vortioxetine | ≥98% | 508233-74-7 | 10mg,50mg,250mg,1g | |||||
| P129402 | Azacyclonol | ≥99% | 115-46-8 | 50mg |
*肾上腺素受体
| 项目号 | 产品名称 | 规格 | CAS | 包装 | 靶点 | IC50 | Ki | pKi | Kd | EC50 | ED50 | pEC50 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D129796 | 甲磺酸多沙唑嗪 | ≥99% | 77883-43-3 | 50mg,100mg,250mg,1g,5g,25g,100g | α-1肾上腺素能受体 | |||||||
| I129899 | Ivabradine HCl | ≥98% | 148849-67-6 | 250mg,1g,5g | 肾上腺素受体 | 2.9 μM | ||||||
| C129903 | Cisatracurium Besylate | ≥98% | 96946-42-8 | 1g | 肾上腺素受体 | |||||||
| A124739 | Asenapine maleate | ≥98% (HPLC) | 85650-56-2 | 10mg,50mg,250mg,1g | 5-HT2C | 10.46 | ||||||
| 5-HT2A | 10.15 | |||||||||||
| 5-HT7 | 9.94 | |||||||||||
| 5-HT2B | 9.75 | |||||||||||
| 5-HT6 | 9.6 | |||||||||||
| C141489 | 卡拉洛尔 | 98% | 57775-29-8 | 250mg,1g | ||||||||
| C120231 | 卡拉洛尔 | 分析标准品 | 57775-29-8 | 10mg | ||||||||
| A129804 | Alfuzosin hydrochloride | ≥98% | 81403-68-1 | 50mg,100mg,250mg,1g | α1受体 | |||||||
| S126595 | Silodosin | ≥99% | 160970-54-7 | 5mg,25mg,100mg,250mg,1g | ||||||||
| N129836 | Nebivolol hydrochloride | ≥97% | 152520-56-4 | 10mg,20mg,100mg,1g,5g | β1-肾上腺素受体 | 0.8 nM | ||||||
| B129688 | BMY 7378 dihydrochloride | ≥98% | 21102-95-4 | 10mg,50mg,100mg | α2C肾上腺素受体 | 6.54 | ||||||
| α1D肾上腺素受体 | 8.2 | |||||||||||
| 5-HT1A受体 | 8.3 | |||||||||||
| P160142 | Prazosin Hydrochloride | ≥98.0% | 19237-84-4 | 50mg,250mg,1g | α肾上腺素受体 | |||||||
| P123277 | 甲磺酸酚妥拉明 | ≥98.0%(TLC) | 65-28-1 | 100mg,500mg,5g | α-肾上腺素受体 | 0.1 μM | ||||||
| M111945 | 酒石酸美托洛尔 | 98% | 56392-17-7 | 5g | β-肾上腺素能受体 | 42 ng/mL | ||||||
| M111944 | 酒石酸美托洛尔 | 分析标准品 | 56392-17-7 | 1g | β-肾上腺素能受体 | 42 ng/mL | ||||||
| T129895 | Terazosin hydrochloride Dihydrate | ≥98% | 70024-40-7 | 100mg,5g,25g | α-肾上腺素能受体 | |||||||
| M129850 | Maprotiline HCl | ≥99%(HPLC) | 10347-81-6 | 1g,5g,25g | 肾上腺素受体 | |||||||
| C123267 | Carvedilol | ≥98%(HPLC) | 72956-09-3 | 1g,5g,25g | α1肾上腺素受体 | |||||||
| β1肾上腺素受体 | ||||||||||||
| N129805 | Naftopidil | ≥98.0% | 57149-07-2 | 5g,25g,500g | α1-肾上腺素能受体 | 58.3 nM | ||||||
| P129843 | Phenoxybenzamine HCl | ≥98% | 63-92-3 | 1g,5g,25g | α受体拮抗剂 | 550 nM | ||||||
| A129820 | Acebutolol HCl | ≥99% | 34381-68-5 | 250mg | β-肾上腺素能受体 | |||||||
| B129336 | Buflomedil HCl | ≥98% | 35543-24-9 | 1g,5g,25g,100g,500g | α-肾上腺素受体 | |||||||
| C134671 | cis-(Z)-Flupentixol Dihydrochloride | ≥98% (HPLC) | 51529-01-2 | 250mg | α肾上腺素能受体 | |||||||
| A132124 | 阿普洛尔 盐酸盐 | ≥99% | 13707-88-5 | 50mg,250mg | β-肾上腺素能受体 | |||||||
| M171294 | Moxisylyte hydrochloride | >99% (TLC) | 964-52-3 | 25g | α-肾上腺素受体 | |||||||
| A151072 | Atipamezole Hydrochloride | 98% | 104075-48-1 | 25mg,100mg,250mg,1g | α2肾上腺素能受体 | |||||||
| A132977 | Atipamezole | ≥98% (HPLC) | 104054-27-5 | 5mg,25mg,100mg,1g | α2肾上腺素能受体 | |||||||
| P160771 | 吡贝地尔 | >98.0%(GC)(T) | 3605-01-4 | 200mg,1g | α2C肾上腺素受体 | 7.2 | ||||||
| α2A肾上腺素受体 | 7.1 | |||||||||||
| D2肾上腺素受体 | 6.9 | |||||||||||
| T102080 | 盐酸坦索罗辛 | 98% | 106463-17-6 | 100mg,500mg,1g | α1A肾上腺素受体 | |||||||
| T136685 | Terazosin Hydrochloride | >98.0%(HPLC) | 63074-08-8 | 50mg,250mg,1g | α-AR | |||||||
| D193380 | 盐酸贝凡洛尔 | 98% | 42864-78-8 | 250mg,1g,5g | β肾上腺素受体 | |||||||
| B129900 | Betaxolol | ≥98% | 63659-18-7 | 10mg,50mg,250mg | β1肾上腺素能受体 | |||||||
| A124776 | 阿替洛尔 | ≥98%,powder | 29122-68-7 | 1g,5g,25g,100g | β1肾上腺素受体 | 0.25 μM | ||||||
| β2肾上腺素受体 | 1 μM | |||||||||||
| Y111137 | 盐酸育亨宾 | 99% | 65-19-0 | 1g,5g,25g | α2肾上腺素受体 | |||||||
| Y111138 | 盐酸育亨宾 | 分析标准品,≥99% | 65-19-0 | 20mg | α2肾上腺素受体 | |||||||
| Y140628 | 盐酸育亨宾 | 97% | 65-19-0 | 1g,5g,25g | α2肾上腺素受体 | |||||||
| L133648 | Labetalol HCl | 98% | 32780-64-6 | 50mg,250mg,1g | α1肾上腺素受体 | |||||||
| β肾上腺素受体 | ||||||||||||
| M126688 | Mirabegron | ≥99% | 223673-61-8 | 5mg,10mg,50mg,250mg,1g | β3肾上腺素受体 | 22.4 nM | ||||||
| X113957 | 盐酸甲苯噻嗪 | 分析标准品 | 23076-35-9 | 100mg | α2肾上腺素能受体 | |||||||
| X113956 | 盐酸甲苯噻嗪 | 98% | 23076-35-9 | 1g,5g,25g,100g | α2肾上腺素能受体 | |||||||
| D194797 | 盐酸阿可乐定(曾用名:盐酸安普乐定) | 97% | 73218-79-8 | 25mg,100mg,250mg,1g,5g | α2-肾上腺素能受体 | |||||||
| I157518 | 茚达特罗马来酸盐 | >98.0%(HPLC) | 753498-25-8 | 20mg,25mg,50mg,100mg,1g | β1肾上腺素受体 | 7.36 | ||||||
| β2肾上腺素受体 | 5.48 | |||||||||||
| I129810 | 盐酸异丙肾上腺素 | ≥99% | 51-30-9 | 5g,25g,100g | β肾上腺素受体 | |||||||
| F129812 | Formoterol Hemifumarate | ≥99% | 43229-80-7 | 10mg,50mg | β2肾上腺素受体 | |||||||
| E129809 | 酒石酸肾上腺素 | ≥98% | 51-42-3 | 1g,5g,25g | α肾上腺素能受体 | |||||||
| β肾上腺素受体 | ||||||||||||
| C102161 | 盐酸可乐定 | 98% | 4205-91-8 | 250mg,1g,5g,100g | α2肾上腺素能受体 | 0.02±0.01 mg/kg | ||||||
| D129407 | Droxidopa | ≥98% | 23651-95-8 | 50mg,250mg | ||||||||
| D129818 | Dexmedetomidine | ≥98% | 113775-47-6 | 50mg,250mg | α2肾上腺素能受体 | |||||||
| P106007 | 盐酸去氧肾上腺素 | 99% | 61-76-7 | 5g,10g,25g,50g,100g | α1肾上腺素能受体 | |||||||
| G156852 | 氯苄氨胍醋酸盐 | >98.0%(HPLC) | 23256-50-0 | 200mg,1g,5g | α2a-肾上腺素能受体 | 8.25 | ||||||
| α2b-肾上腺素能受体 | 7.01 | |||||||||||
| α2c-肾上腺素能受体 | <5 | |||||||||||
| N113459 | Naphazoline hydrochloride | 99% | 550-99-2 | 5g,25g,100g,500g | ||||||||
| R124692 | 利托君盐酸盐 | ≥98% | 23239-51-2 | 250mg,1g,5g | β-2肾上腺素能受体 | |||||||
| D129813 | Dexmedetomidine HCl | ≥98% | 145108-58-3 | 5mg,10mg,50mg,100mg | α-2肾上腺素受体 | |||||||
| M129911 | Medetomidine HCl | ≥99% | 86347-15-1 | 10mg,25mg,50mg,100mg | α2-肾上腺素受体 | 1.08 nM | ||||||
| T101308 | 替扎尼定 | 98% | 64461-82-1 | 5g,25g | α2-肾上腺素受体 | |||||||
| D129815 | Detomidine HCl | ≥98% | 90038-01-0 | 50mg,250mg,1g | ||||||||
| S129883 | Scopine | ≥98% | 498-45-3 | 25mg,100mg,200mg,500mg | α1-肾上腺素能受体 | |||||||
| N107258 | 重酒石酸去甲肾上腺素一水合物 | ≥98%（HPLC),USP | 108341-18-0 | 250mg,1g,5g,25g | α-肾上腺素能受体 | |||||||
| X139232 | 赛拉嗪 | ≥98.0%(HPLC) | 7361-61-7 | 1g,5g,10g,25g | α2-肾上腺素受体 | |||||||
| T128967 | 特布他林半硫酸盐 | 98% | 23031-32-5 | 1g,5g,25g | β2-肾上腺素能受体 | 53 nM | ||||||
| T128967 | 特布他林半硫酸盐 | 分析标准品 | 23031-32-5 | 100mg | β2-肾上腺素能受体 | 53 nM | ||||||
| I157589 | 异丙肾上腺素硫酸盐二水合物 | >98.0%(HPLC)(N) | 299-95-6 | 1g,5g,25g | β-肾上腺素能受体 | |||||||
| X129373 | Xylometazoline HCl | ≥98.0%(HPLC) | 1218-35-5 | 1g,5g,25g,100g | α2B肾上腺素受体 | 4 μM | ||||||
| A114817 | 双甲脒 | 分析标准品,99% | 33089-61-1 | 250mg | α2肾上腺素受体 | |||||||
| A114818 | 双甲脒 | 97% | 33089-61-1 | 1g,5g | α2肾上腺素受体 | |||||||
| G133358 | Guanfacine hydrochloride | ≥98%(HPLC) | 29110-48-3 | 10mg,50mg,100mg,250mg | α2A-肾上腺素受体 | |||||||
| I134069 | 异舒普林 盐酸盐 | 分析标准品 | 579-56-6 | 1g,5g | β-肾上腺素能受体 | |||||||
| I125935 | Indacaterol | ≥99% | 312753-06-3 | 50mg,250mg | β1-肾上腺素能受体 | 7.36 | ||||||
| β2-肾上腺素能受体 | 5.48 | |||||||||||
| B134443 | Bambuterol Hydrochloride | ≥98% (HPLC) | 81732-46-9 | 1g,5g | β-肾上腺素能受体 | |||||||
| D134211 | DL-去甲肾上腺素 盐酸盐 | 97% | 55-27-6 | 1g,5g,25g | ||||||||
| S107339 | 辛弗林 | 分析标准品,≥98% | 94-07-5 | 20mg | ||||||||
| S107340 | 辛弗林 | 98% | 94-07-5 | 5g,25g | ||||||||
| N109573 | L-去甲肾上腺素 | 98% | 51-41-2 | 250mg,1g | α1肾上腺素受体 | 56 nM | ||||||
| α2A肾上腺素受体 | 330 nM | |||||||||||
| β1肾上腺素受体 | 740 nM | |||||||||||
| B136672 | Brimonidine | >98.0%(HPLC) | 59803-98-4 | 250mg,1g,5g | ||||||||
| D137302 | 双氢麦角胺甲磺酸盐 | >95.0%(HPLC) | 6190-39-2 | 100mg,250mg,1g | ||||||||
| D135863 | Dihydro Ergotamine Mesylate | 药典级 | 6190-39-2 | 250mg | ||||||||
| A129906 | Adrenalone HCl Hydrate | ≥98% | 62-13-5 | 1g,5g,25g,100g | α-1肾上腺素受体 | |||||||
| D129628 | 醋酸去氧皮质酮 | ≥99% | 56-47-3 | 250mg,1g,5g | ||||||||
*组胺受体
| 项目号 | 产品名称 | 规格 | CAS | 包装 | 靶点 | IC50 | Ki |
|---|---|---|---|---|---|---|---|
| C115479 | Cetirizine dihydrochloride | 98% | 83881-52-1 | 1g,5g,25g,100g | 组胺受体 | ||
| F129253 | Fexofenadine HCl | ≥98% | 153439-40-8 | 10mg,50mg,1g,5g | 组胺H1受体 | 246 nM | |
| E129640 | Epinastine HCl | ≥99% | 108929-04-0 | 50mg,250mg,1g,5g,25g | 组胺受体 | ||
| O159894 | Olopatadine Hydrochloride | >98.0%(HPLC) | 140462-76-6 | 250mg,1g | 组胺受体 | 559 μM | |
| A124055 | 安他唑啉 盐酸盐 | 98% | 2508-72-7 | 1g,5g,25g,100g | 组胺H1受体 | ||
| K124652 | 酮替芬延胡索酸 | 99% | 34580-14-8 | 100mg,250mg,1g,5g,25g | 组胺H1受体 | ||
| A129250 | Azatadine dimaleate | ≥98% | 3978-86-7 | 10mg,50mg,250mg,1g | 组胺受体 | 6.5 nM | |
| 胆碱能 | 10 nM | ||||||
| H107699 | 橙皮素 | 分析标准品,≥98% | 520-33-2 | 20mg | 组胺受体 | ||
| H107700 | 橙皮素 | 97% | 520-33-2 | 1g,5g,25g,100g | 组胺受体 | ||
| C136571 | CarbinoxamineMaleateSalt | - | 3505-38-2 | 5g,10g,25g | 组胺-H1受体 | ||
| D129627 | Doxylamine Succinate | ≥99% | 562-10-7 | 1g,5g,10g,25g,50g | 组胺H1受体 | ||
| B102783 | 盐酸倍他司汀 | 99% | 5579-84-0 | 1g,5g,10g,25g,100g | 组胺H3受体 | 1.9 μM | |
| C129211 | Clemastine Fumarate | ≥98% (HPLC) | 14976-57-9 | 100mg,250mg,500mg,1g | 组胺H1受体 | 3 nM | |
| L129669 | Latrepirdine | ≥96% | 97657-92-6 | 5mg,10mg,50mg | |||
| L129223 | Loratadine | ≥98% | 79794-75-5 | 100mg,1g,5g,25g | B(0)AT2 | 4 μM | |
| B129218 | Bepotastine Besilate | 98% | 190786-44-8 | 10mg,50mg,100mg,250mg,1g | |||
| M129226 | Mianserin HCl | ≥98% | 21535-47-7 | 50mg,250mg,1g,5g | 组胺受体 | ||
| M157977 | 美喹他嗪 | >98.0%(GC) | 29216-28-2 | 100mg,250mg,1g | 组胺H1受体 | ||
| A129214 | Azelastine HCl | ≥98%(HPLC) | 79307-93-0 | 100mg,250mg,1g,5g,25g | 组胺受体 | ||
| R129213 | 盐酸雷尼替丁 | ≥98%(HPLC) | 66357-59-3 | 1g,5g,25g | 组胺H2-受体 | 3.3±1.4 μM | |
| D129201 | Diphenhydramine Hydrochloride | ≥98% (HPLC) | 147-24-0 | 5g,25g,100g,500g | 组胺H1受体 | ||
| D155989 | Desloratadine | >98.0%(HPLC)(T) | 100643-71-8 | 100mg,250mg,1g,5g,25g | 组胺H1受体 | 51nM | |
| C129233 | 马来酸氯苯那敏 | ≥99% | 113-92-8 | 5g,25g,100g,500g | 组胺H1受体 | 12nM | |
| M129292 | Meclizine 2HCl | ≥98% | 1104-22-9 | 250mg,1g,5g,25g | 组胺H1受体 | ||
| M129245 | Mizolastine | ≥98% | 108612-45-9 | 1g,5g | 组胺H1受体 | 47 nM | |
| C102301 | Cimetidine | 99% | 51481-61-9 | 5g,25g,100g | 组胺H2受体 | ||
| L129237 | Lafutidine | ≥99% | 118288-08-7 | 10mg,50mg,250mg | 组胺H2受体 | ||
| N129229 | Nizatidine | ≥98% | 76963-41-2 | 5g,25g | 组胺H2受体 | 0.9 nM | |
| AChE | 6.7 nM | ||||||
| H168667 | 羟嗪 二盐酸盐 | 98% | 2192-20-3 | 10mg,10g | 组胺H1受体 | 19 nM | |
| B129275 | Brompheniramine hydrogen maleate | ≥98% | 980-71-2 | 50mg,250mg,1g,5g,25g | 组胺H1受体 | ||
| J129258 | JNJ-7777120 | ≥98% (HPLC) | 459168-41-3 | 10mg,50mg | 组胺H4受体 | 4.5 nM | |
| P129261 | Pemirolast potassium | ≥99% | 100299-08-9 | 10mg,50mg,250mg | 组胺H1受体 | ||
| L124802 | 盐酸左旋西替利嗪 | ≥98% (HPLC) | 130018-87-0 | 1g,5g | 组胺H1受体 | ||
| P129451 | Pheniramine Maleate | ≥99% | 132-20-7 | 1g,5g | |||
| C119225 | 咳平盐酸盐 | 分析标准品 | 14984-68-0 | 5g,10g,25g | |||
| R129246 | 盐酸罗沙替丁醋酸酯 | ≥99% | 93793-83-0 | 200mg,1g,5g,25g | 组胺H2受体 | 3.2 μM | |
| A151022 | 阿伐斯汀 | >98.0%(HPLC) | 87848-99-5 | 20mg,100mg | |||
| E134559 | 富马酸依美斯汀 | ≥98.0%(HPLC) | 87233-62-3 | 50mg,250mg,1g,5g | 组胺H1受体 | ||
| M118323 | 美海屈林萘二磺酸盐 | 98% | 6153-33-9 | 1g,5g,25g | |||
| F129242 | Famotidine | ≥99% | 76824-35-6 | 5g,25g | 组胺H2受体 | 0.6 mM | |
| P133927 | 盐酸异丙嗪 | >98.0%(HPLC) | 58-33-3 | 25g,100g | 组胺H1受体 | ||
| L129221 | Lidocaine | ≥99% | 137-58-6 | 5g,25g,100g | 组胺H1受体 | >32 μM | |
| H111796 | 组胺 | 96% | 51-45-6 | 1g,5g | |||
| H110868 | 组胺二盐酸盐 | 98% | 56-92-8 | 5g,25g,100g | 组胺H1受体 | ||
| 组胺H2受体 | |||||||
| B152161 | 甲磺酸倍他司汀 | >99.0%(HPLC) | 54856-23-4 | 25g,100g,500g |
July 9, 2020
|
View: 885
|
Categories: 特色产品专题
| Tags: <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/tag/smallmolecule">小分子</a>, <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/tag/inhibitor">抑制剂</a>, <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/tag/agonist">激动剂</a>, <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/tag/antagonist">拮抗剂</a>, <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/tag/Gprotein">G蛋白</a>
|
By: <a class="mp-info" href="https://www.aladdin-e.com/zh_cn/blog/author/n-a">aladdin</a>
About the Author
【阿拉丁】科研实验服务目录
October 15, 2026
【阿拉丁】细胞检测产品买三免一
October 13, 2026
【阿拉丁】光引发剂：作用机理与选型逻辑
September 23, 2026
【阿拉丁】脂质≠脂肪！从细胞代谢到 mRNA 递送认识脂质的多重功能
September 17, 2026
【阿拉丁】mRNA疫苗研发与生产相关产品
September 11, 2026
危险品化学品经营许可证（带存储）